FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281620281> ?p ?o ?g. }

• W4281620281 endingPage "e21174" @default.
• W4281620281 startingPage "e21174" @default.
• W4281620281 abstract "e21174 Background: Low dose radiation (LDRT) can potentially enhance the synergistic anti-tumor effect in metastatic NSCLC when combining with immunotherapy and SBRT. We previously reported the safety and tolerability of this new combination strategy. Here we presented the updated safety and efficacy data. Methods: This phase I study included a dose escalation phase (aimed to determine the optimal LDRT dose) and a dose expansion phase. Eligible patients had histologically or cytologically confirmed NSCLC, stage IV, PD-L1 positive (TPS ≥ 1%), and at least 2 extra-cranial tumor lesions. Patients received SBRT (30Gy/3f) to a small lesion and LDRT to a large lesion concurrently, followed by sintilimab (200mg i.v., q3w) started within 7 days after radiation completion until disease progression, unacceptable toxicities or reached a maximum of 24 months. Primary endpoints were safety and tolerability; secondary endpoints included objective response rate (ORR), progression-free survival (PFS), and overall survival (OS). Results: Between 4/2019 and 10/2021, 29 patients were enrolled and treated. No dose limiting toxicities were observed during the dose escalation phase and 4Gy/2f was chosen as recommended LDRT dose for expansion phase. Most patients were male (89.7%) with adenocarcinoma (58.6%). 34.4% patients had PD-L1 TPS ≥ 50%. Until data cutoff (1/8/2022), the median follow-up was 15.5 (range: 1.2-32.5) months. Treatment-related adverse events (TRAEs) occurred in 96.6% patients (28/29) and 20.7% (6/29) were grade 3-4. Permanent discontinuation due to TRAEs occurred in 6.9% (2/29) patients. Eight patients experienced pneumonitis, including 1 grade 1, 6 grade 2 and 1 grade 3. No grade 5 TRAE was observed. 51.7% (15/29) patients had potential immune-related AEs. Of the 28 patients who received at least one tumor assessment, the ORR was 60.7% (95%CI:40.6%-78.5%) and the confirmed ORR was 57.1% (95%CI:37.2%-75.5%). The median duration of response was 13.6 months (95%CI:7.9-19.3), and 4 patients maintained response after reaching the maximum treatment of 2 years. The disease control rate (DCR) was 78.6% (95%CI: 59.1%-91.7%). The median PFS was 8.6 months (95%CI: 5.7-11.5), the 12-month PFS rate was 39.6%, and the median OS was not reach. 17 patients were enrolled in the LDRT 4Gy/2f does group and 16 were evaluable. The ORR was 62.5%, the confirmed ORR was 56.3%, and the DCR was 81.25%. The median PFS was 9.0 months. Exploratory analysis revealed that patients with lower neutrophil to lymphocyte ratio (NLR) had longer PFS. Conclusions: This is the first prospective phase I study to evaluate a new combination with SBRT, LDRT and anti-PD-1 therapy. The result suggested it was tolerable and feasible, with encouraging ORR and PFS. The strategy of adding SBRT and LDRT to immuno-based systemic therapy in treatment naïve metastatic NSCLC warranted further exploration. Clinical trial information: NCT03812549." @default.
• W4281620281 created "2022-06-13" @default.
• W4281620281 creator A5003445392 @default.
• W4281620281 creator A5009330754 @default.
• W4281620281 creator A5010431622 @default.
• W4281620281 creator A5014692144 @default.
• W4281620281 creator A5015376105 @default.
• W4281620281 creator A5018244700 @default.
• W4281620281 creator A5022128135 @default.
• W4281620281 creator A5023519850 @default.
• W4281620281 creator A5026038096 @default.
• W4281620281 creator A5027809084 @default.
• W4281620281 creator A5032976671 @default.
• W4281620281 creator A5051672771 @default.
• W4281620281 creator A5053959485 @default.
• W4281620281 creator A5061953621 @default.
• W4281620281 creator A5067387552 @default.
• W4281620281 creator A5080438223 @default.
• W4281620281 creator A5081534462 @default.
• W4281620281 creator A5086664284 @default.
• W4281620281 creator A5087045827 @default.
• W4281620281 date "2022-06-01" @default.
• W4281620281 modified "2023-10-14" @default.
• W4281620281 title "Safety and efficacy of sintilimab in combination with SBRT and LDRT in PD-L1 positive treatment naïve-stage IV non-small cell lung cancer: A phase I study (IHC study)." @default.
• W4281620281 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.e21174" @default.
• W4281620281 hasPublicationYear "2022" @default.
• W4281620281 type Work @default.
• W4281620281 citedByCount "0" @default.
• W4281620281 crossrefType "journal-article" @default.
• W4281620281 hasAuthorship W4281620281A5003445392 @default.
• W4281620281 hasAuthorship W4281620281A5009330754 @default.
• W4281620281 hasAuthorship W4281620281A5010431622 @default.
• W4281620281 hasAuthorship W4281620281A5014692144 @default.
• W4281620281 hasAuthorship W4281620281A5015376105 @default.
• W4281620281 hasAuthorship W4281620281A5018244700 @default.
• W4281620281 hasAuthorship W4281620281A5022128135 @default.
• W4281620281 hasAuthorship W4281620281A5023519850 @default.
• W4281620281 hasAuthorship W4281620281A5026038096 @default.
• W4281620281 hasAuthorship W4281620281A5027809084 @default.
• W4281620281 hasAuthorship W4281620281A5032976671 @default.
• W4281620281 hasAuthorship W4281620281A5051672771 @default.
• W4281620281 hasAuthorship W4281620281A5053959485 @default.
• W4281620281 hasAuthorship W4281620281A5061953621 @default.
• W4281620281 hasAuthorship W4281620281A5067387552 @default.
• W4281620281 hasAuthorship W4281620281A5080438223 @default.
• W4281620281 hasAuthorship W4281620281A5081534462 @default.
• W4281620281 hasAuthorship W4281620281A5086664284 @default.
• W4281620281 hasAuthorship W4281620281A5087045827 @default.
• W4281620281 hasConcept C126322002 @default.
• W4281620281 hasConcept C126894567 @default.
• W4281620281 hasConcept C143998085 @default.
• W4281620281 hasConcept C197934379 @default.
• W4281620281 hasConcept C2776256026 @default.
• W4281620281 hasConcept C2778375690 @default.
• W4281620281 hasConcept C2778715236 @default.
• W4281620281 hasConcept C2989005 @default.
• W4281620281 hasConcept C71924100 @default.
• W4281620281 hasConceptScore W4281620281C126322002 @default.
• W4281620281 hasConceptScore W4281620281C126894567 @default.
• W4281620281 hasConceptScore W4281620281C143998085 @default.
• W4281620281 hasConceptScore W4281620281C197934379 @default.
• W4281620281 hasConceptScore W4281620281C2776256026 @default.
• W4281620281 hasConceptScore W4281620281C2778375690 @default.
• W4281620281 hasConceptScore W4281620281C2778715236 @default.
• W4281620281 hasConceptScore W4281620281C2989005 @default.
• W4281620281 hasConceptScore W4281620281C71924100 @default.
• W4281620281 hasIssue "16_suppl" @default.
• W4281620281 hasLocation W42816202811 @default.
• W4281620281 hasOpenAccess W4281620281 @default.
• W4281620281 hasPrimaryLocation W42816202811 @default.
• W4281620281 hasRelatedWork W2054186137 @default.
• W4281620281 hasRelatedWork W2059313976 @default.
• W4281620281 hasRelatedWork W2089245388 @default.
• W4281620281 hasRelatedWork W2792428998 @default.
• W4281620281 hasRelatedWork W2896659597 @default.
• W4281620281 hasRelatedWork W2996750011 @default.
• W4281620281 hasRelatedWork W3000507271 @default.
• W4281620281 hasRelatedWork W3115293888 @default.
• W4281620281 hasRelatedWork W3138587145 @default.
• W4281620281 hasRelatedWork W4320710015 @default.
• W4281620281 hasVolume "40" @default.
• W4281620281 isParatext "false" @default.
• W4281620281 isRetracted "false" @default.
• W4281620281 workType "article" @default.